Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$55 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
33.37
Debt to Equity
0
ROE
-0.93 %
ROCE
--
Div. Yield
0 %
Book Value
2.79
EPS
--
CFO
$-64.30 Mln
EBITDA
$-27.98 Mln
Net Profit
$-174.82 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Rafael Holdings Inc. Class B (RFL)
| 4.85 | -12.63 | -17.62 | 1.17 | -6.55 | -33.04 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Rafael Holdings Inc. Class B (RFL)
| -9.76 | -2.14 | -63.33 | -78.13 | 30.72 | 124.97 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 5.68 | 757.24 | 4.54 | 11.39 | |
| 6.51 | 898.43 | -- | -1.97 | |
| 42.63 | 2,452.32 | 33.17 | 11.01 | |
| 17.14 | 460.52 | 171.4 | 0.57 |
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and... Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey. Read more
Founder & Executive Chairman
Mr. Howard S. Jonas
Founder & Executive Chairman
Mr. Howard S. Jonas
Headquarters
Newark, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Rafael Holdings Inc Class B (RFL) stood at $ 90 Mln as on 31-Jan-25
The share price of Rafael Holdings Inc Class B (RFL) is $1.73 (NYSE) as of 25-Apr-2025 16:10 EDT. Rafael Holdings Inc Class B (RFL) has given a return of -6.55% in the last 3 years.
Rafael Holdings Inc Class B (RFL) has a market capitalisation of $ 55 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rafael Holdings Inc Class B (RFL) is 0.79 times as on 25-Apr-2025, a 34% discount to its peers’ median range of 1.19 times.
Since, TTM earnings of Rafael Holdings Inc Class B (RFL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rafael Holdings Inc Class B (RFL) and enter the required number of quantities and click on buy to purchase the shares of Rafael Holdings Inc Class B (RFL).
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
The CEO & director of Mr. Howard S. Jonas. is Rafael Holdings Inc Class B (RFL), and CFO & Sr. VP is Mr. Howard S. Jonas.
There is no promoter pledging in Rafael Holdings Inc Class B (RFL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
243
|
|
|
89
|
|
|
73
|
|
|
46
|
| Rafael Holdings Inc. Class B (RFL) | Ratios |
|---|---|
|
Return on equity(%)
|
-25.4
|
|
Operating margin(%)
|
-11188.1
|
|
Net Margin(%)
|
-7148.16
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Rafael Holdings Inc Class B (RFL) was $0 Mln.
$0.02
(
